Prosensa Holding NV Company Profile (NYSE:RNA)

About Prosensa Holding NV

Prosensa Holding NV logoProsensa Holding N.V., formerly Prosensa Holding B.V., is a biotechnology company engaged in the discovery and development of ribonucleic acid-modulating (RNA)-modulating, therapeutics for the treatment of genetic disorders. The Company's primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy, myotonic dystrophy and Huntington's disease. The Company's clinical portfolio of RNA-based product candidates is focused on the treatment of Duchenne muscular dystrophy (DMD). The Company's platform technology allows the development of RNA-modulating therapeutics that either interferes with splicing (exon skipping, exon inclusion, or splice mutation correction), remove mutant RNA, or block RNA expression, for different indications.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: RNA
  • CUSIP:
Key Metrics:
  • Previous Close: $19.00
  • 50 Day Moving Average: $0
  • 200 Day Moving Average: $17
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -19.00
  • P/E Growth: 0
  • Market Cap: $N/A
Additional Links:

Analyst Ratings

Consensus Ratings for Prosensa Holding NV (NYSE:RNA) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Prosensa Holding NV (NYSE:RNA)
Show:
DateFirmActionRatingPrice TargetDetails
11/25/2014Credit Suisse Group AGBoost Price TargetNeutral$9.00 -> $20.00View Rating Details
11/25/2014Roth CapitalDowngradeBuy -> NeutralView Rating Details
11/25/2014KBC SecuritiesDowngradeBuy -> Hold$17.00 -> $19.80View Rating Details
10/20/2014JPMorgan Chase & Co.UpgradeUnderweight -> Overweight$4.40 -> $18.00View Rating Details
(Data available from 9/26/2014 forward)

Earnings

Earnings History for Prosensa Holding NV (NYSE:RNA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/17/2014Q314($0.25)($0.29)ViewN/AView Earnings Details
8/12/2014Q214($0.36)($0.29)ViewN/AView Earnings Details
5/20/2014Q114$0.01$0.26ViewN/AView Earnings Details
3/18/2014($0.14)($0.12)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Prosensa Holding NV (NYSE:RNA)
Current Year EPS Consensus Estimate: $-1 EPS
Next Year EPS Consensus Estimate: $-1 EPS

Dividends

Dividend History for Prosensa Holding NV (NYSE:RNA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Prosensa Holding NV (NYSE:RNA)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Prosensa Holding NV (NYSE:RNA)
DateHeadline
finance.yahoo.com logoBioMarin Upgraded to Strong Buy, Is It in Your Portfolio? - Analyst Blog (NYSE:RNA)
finance.yahoo.com - April 29 at 4:32 PM
finance.yahoo.com logoHow bubbles are blown: Biotech edition (NYSE:RNA)
finance.yahoo.com - March 31 at 7:53 AM
investors.com logoBioMarin Pharma Hits All-Time High (NYSE:RNA)
news.investors.com - March 27 at 6:40 PM
insidermonkey.com logoBioMarin Pharmaceutical Inc. (BMRN) and Other Top New Picks of Healthcare-Focused Visium Asset Management (NYSE:RNA)
www.insidermonkey.com - March 3 at 10:09 AM
investors.com logoWhy Muscular Dystrophy Is Biotech's Favorite Orphan (NYSE:RNA)
news.investors.com - February 19 at 4:59 PM
noodls.com logoProsensa Announces Voluntary Delisting and Advance Liquidation Distribution (NYSE:RNA)
www.noodls.com - February 10 at 4:17 PM
noodls.com logoProsensa Announces Intent to Voluntarily Delist From NASDAQ (NYSE:RNA)
www.noodls.com - January 31 at 1:53 AM
noodls.com logoBioMarin Announces Final Results of Tender Offer for Prosensa's Shares and Completion of Subsequent Offering Period (NYSE:RNA)
www.noodls.com - January 30 at 8:09 AM
finance.yahoo.com logoBioMarin to Raise Funds to Finance Prosensa Acquisition - Analyst Blog (NYSE:RNA)
finance.yahoo.com - January 22 at 6:00 PM
finance.yahoo.com logoState Of The Union Lights Up Biotech (NYSE:RNA)
finance.yahoo.com - January 21 at 6:25 AM
finance.yahoo.com logoBioMarin Gains on Vimizim 2014 View, Batten Disease Data - Analyst Blog (NYSE:RNA)
finance.yahoo.com - January 14 at 5:10 PM
noodls.com logoProsensa Announces Shareholder Approval of Certain Matters Relating to the BioMarin Tender Offer (NYSE:RNA)
www.noodls.com - January 13 at 10:43 AM
finance.yahoo.com logoUS STOCKS-S&P 500 ticks up to record on central bank bets (NYSE:RNA)
finance.yahoo.com - November 24 at 4:49 PM
finance.yahoo.com logoUS STOCKS-Wall St up on central bank bets, deals support (NYSE:RNA)
finance.yahoo.com - November 24 at 3:19 PM
finance.yahoo.com logoUS STOCKS-Wall St hits new records, but telecom weighs on Dow (NYSE:RNA)
finance.yahoo.com - November 24 at 12:34 PM
finance.yahoo.com logoUS STOCKS-Wall St hits new records, boosted by cyclicals (NYSE:RNA)
finance.yahoo.com - November 24 at 11:18 AM
finance.yahoo.com logoBuying Glaxo's Biotech Stock Throwbacks Proves Profitable (NYSE:RNA)
finance.yahoo.com - November 24 at 10:57 AM
finance.yahoo.com logoUS STOCKS-Wall St surges to new records, boosted by cyclicals (NYSE:RNA)
finance.yahoo.com - November 24 at 10:04 AM
247wallst.com logoBig News for Ebola Stocks (NYSE:RNA)
247wallst.com - November 24 at 9:15 AM
finance.yahoo.com logoUS STOCKS-Futures point to higher open on merger activity (NYSE:RNA)
finance.yahoo.com - November 24 at 8:52 AM
finance.yahoo.com logoUS STOCKS-Futures rise, boosted by merger activity (NYSE:RNA)
finance.yahoo.com - November 24 at 8:14 AM
sg.finance.yahoo.com logoBioMarin Pharma offers about $680M for Prosensa (NYSE:RNA)
sg.finance.yahoo.com - November 24 at 7:35 AM
finance.yahoo.com logoBioMarin to buy Prosensa in $840 mln deal (NYSE:RNA)
finance.yahoo.com - November 24 at 6:24 AM

Social

Prosensa Holding NV (NYSE:RNA) Chart for Monday, September, 26, 2016


Last Updated on 9/26/2016 by MarketBeat.com Staff